TY - JOUR
T1 - Cost-effectiveness of rapid diagnostic assays that perform directly on blood samples for the diagnosis of septic shock
AU - Shehadeh, Fadi
AU - Zacharioudakis, Ioannis M.
AU - Zervou, Fainareti N.
AU - Mylonakis, Eleftherios
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/8
Y1 - 2019/8
N2 - Molecular diagnostic assays that test directly whole blood provide the ability to decrease inappropriate antimicrobial therapy and improve survival in patients with septic shock. We developed a decision analysis model to evaluate the cost-effectiveness of the addition of molecular assays to blood cultures in adults admitted to medical ICUs with septic shock. Under baseline assumptions, the use of molecular diagnostic methods was cost-saving in all cases that the length of hospital stay differed by 2 and 4 days between patients receiving appropriate and inappropriate antimicrobial therapy. In the case that the length of stay was the same, the use of molecular methods was cost-effective with an estimated incremental cost-effectiveness ratio (ICER) < $3000 per death averted. In the extreme that the length of stay between the 2 groups was the same, the highest cost reached was when the cost of the assay was $1000, with the estimated ICER being < $20,000 per death averted.
AB - Molecular diagnostic assays that test directly whole blood provide the ability to decrease inappropriate antimicrobial therapy and improve survival in patients with septic shock. We developed a decision analysis model to evaluate the cost-effectiveness of the addition of molecular assays to blood cultures in adults admitted to medical ICUs with septic shock. Under baseline assumptions, the use of molecular diagnostic methods was cost-saving in all cases that the length of hospital stay differed by 2 and 4 days between patients receiving appropriate and inappropriate antimicrobial therapy. In the case that the length of stay was the same, the use of molecular methods was cost-effective with an estimated incremental cost-effectiveness ratio (ICER) < $3000 per death averted. In the extreme that the length of stay between the 2 groups was the same, the highest cost reached was when the cost of the assay was $1000, with the estimated ICER being < $20,000 per death averted.
KW - Cost-effectiveness
KW - ICU
KW - Molecular assays
KW - Rapid diagnostics
KW - Septic shock
UR - http://www.scopus.com/inward/record.url?scp=85063282119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063282119&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.02.018
DO - 10.1016/j.diagmicrobio.2019.02.018
M3 - Article
C2 - 30922592
AN - SCOPUS:85063282119
SN - 0732-8893
VL - 94
SP - 378
EP - 384
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 4
ER -